New Zealand customs officials recently seized 14 injectable pens labelled as Fitaro and Orsema – semaglutide-based medications manufactured by Incepta Pharmaceuticals, a drugmaker from Bangladesh. These drugs, meant to provide an affordable alternative to Novo Nordisk’s Ozempic, underscore a surge in demand for lower-cost versions of the popular diabetes and weight loss medication. Ozempic and its anti-obesity counterpart, Wegovy, contain…